Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group.

Autor: Schaefer R; Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America., Donaldson L; Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America., Leus M; Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America., Osakwe CE; Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America., Chimukangara B; National Institutes of Health, Bethesda, Maryland, United States of America., Dalal S; Global HIV, Hepatitis, and STIs Programmes, World Health Organization, Geneva, Switzerland., Duerr A; Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Gao F; Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Glidden DV; University of California, San Francisco, California, United States of America., Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil., Justman J; ICAP at Columbia University, Mailman School of Public Health, New York, New York, United States of America., Kumwenda G; AVAC, Southern Region, Malawi., Laeyendecker O; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Lee HY; Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America., Maldarelli F; National Cancer Institute, Bethesda, Maryland, United States of America., Mayer KH; The Fenway Institute, Fenway Health, Boston, Massachusetts, United States of America.; Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, United States of America., Murray J; Independent consultant, Lewes, Delaware, United States of America., Parekh BS; Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America., Rice B; The University of Sheffield, Sheffield, United Kingdom., Robertson MN; BDI Consulting, Nipomo, California, United States of America., Saito S; ICAP at Columbia University, Mailman School of Public Health, New York, New York, United States of America., Vannappagari V; ViiV Healthcare, Durham, North Carolina, United States of America., Warren M; AVAC, New York, New York, United States of America., Zeballos D; Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil., Zinserling J; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Miller V; Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America.
Jazyk: angličtina
Zdroj: PLOS global public health [PLOS Glob Public Health] 2024 Oct 24; Vol. 4 (10), pp. e0003878. Date of Electronic Publication: 2024 Oct 24 (Print Publication: 2024).
DOI: 10.1371/journal.pgph.0003878
Abstrakt: Competing Interests: We have read the journal's policy and the authors of this manuscript have the following competing interests to declare: Forum for Collaborative Research, as an organization, receives grants from the pharmaceutical industry but these are unrestricted and not specific to the work described in this article. KHM has received unrestricted research grants from Gilead Sciences, Merck & Co., Inc., and ViiV Healthcare. JM is a paid consultant for both Gilead Sciences in the area of HIV prevention. BSP, as an inventor of the LAg-Avidity EIA at CDC, receives a portion of the royalties from the sale of the test kits, as per policy of the U.S. government. MNR received consulting fees from the Bill and Melinda Gates Foundation, Merck, the Forum for Collaborative research, and the International AIDS Vaccine Initiative in 2024. VV is a full-time employee of ViiV Healthcare and owns GSK stock. HYL received NIH NIAID grant support for genomic HIV incidence assay research. All other authors have declared that no competing interests exist.
Databáze: MEDLINE